| Bid | 4.35 |
| Market Cap | 255.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -15.14 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.02 |
| Volume | 406,194 |
| Avg. Volume (20D) | 611,600 |
| Open | 4.55 |
| Previous Close | 4.53 |
| Day's Range | 4.35 - 4.55 |
| 52-Week Range | 3.46 - 6.75 |
| Beta | undefined |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...
Analyst Forecast
According to 2 analyst ratings, the average rating for VNDA stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 253.08% from the latest price.
Next Earnings Release
Analysts project revenue of $51.25M, reflecting a 13.21% YoY growth and earnings per share of -0.17, making a 325.00% increase YoY.
3 weeks ago · seekingalpha.com
Vanda Pharmaceuticals: Net-Net Status Presents A Trading OpportunityVanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 resul...
